The children's vaccine initiative : achieving the vision / / Violaine S. Mitchell, Nalini M. Philipose, and Jay P. Sanford, editors ; Committee on the Children's Vaccine Initiative : Planning Alternative Strategies Toward Full U.S. Participation, Division of International Health, Institute of Medicine |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Washington, D.C., : National Academy Press, 1993 |
Descrizione fisica | 1 online resource (xiii, 221 pages) : illustrations |
Disciplina | 614.4/7/083 |
Altri autori (Persone) |
SanfordJay P. <1928->
MitchellViolaine S PhiliposeNalini M |
Soggetto topico |
Vaccination of children
Vaccines Immunization of children Vaccination Children Infants Immunization Programs Child Immunization Schedule Infant |
ISBN |
9786610196012
9781280196010 1280196017 9780309585835 030958583X 9780585143521 0585143528 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
The Children's Vaccine Initiative -- Copyright -- Preface -- Acknowledgments -- Contents -- 1 Executive Summary -- THE CHILDREN'S VACCINE INITIATIVE -- THE INSTITUTE OF MEDICINE REPORT -- COMMITTEE FINDINGS -- Resources and Infrastructure -- Vaccine Demand and Supply -- Demand -- Supply -- Innovation -- Investing in New and Improved Vaccines -- Stages of Vaccine Development -- Pilot Production -- Clinical Trials -- Scaleup and Large-Scale Manufacture -- Technology Transfer -- A STRATEGY TO ENHANCE U.S. PARTICIPATION -- NOTE -- REFERENCE -- 2 Why a Children's Vaccine Initiative? -- PROGRESS TOWARD UNIVERSAL CHILDHOOD IMMUNIZATION -- Limits of the Expanded Program on Immunization -- THE CHILDREN'S VACCINE INITIATIVE -- Characteristics of CVI Vaccines -- Vaccines Should Be Single Dose -- Vaccines Should Be Administered Near Birth -- Vaccines Should Be Combined in Novel Ways -- Vaccines Should Be Heat Stable -- Vaccines Should Be Effective Against Additional Diseases -- Vaccines Should Be Affordable -- Concerns About the CVI -- RELEVANCE OF THE CVI TO U.S. IMMUNIZATION EFFORTS -- Status of Immunization Efforts in the United States -- A Role for the CVI in the United States -- REFERENCES -- 3 Resources and Infrastructure -- RESOURCES IN THE UNITED STATES -- U.S. Federal Agencies and Programs -- U.S. Agency for International Development -- Center for Biologics Evaluation and Research, U.S. Food and Drug Administration -- Centers for Disease Control and Prevention -- U.S. Department of Defense -- National Institutes of Health -- National Vaccine Program -- Other Federal Programs -- U.S. State Vaccine Manufacturers -- Massachusetts -- Michigan -- U.S.-Based Pharmaceutical Firms -- Connaught Laboratories, Inc. -- Lederle-Proxis Biologicals -- Merck & -- Co., Inc. -- SmithKline Beecham -- Wyeth-Ayerst -- Development-Stage Companies.
North American Vaccine -- MedImmune -- Univax Biologics, Inc. -- Nongovernmental Organizations -- The Children's Defense Fund -- March of Dimes Birth Defects Foundation -- Rockefeller Foundation -- Rotary Foundation -- INTERNATIONAL RESOURCES -- Multilateral Organizations -- Pan American Health Organization -- PAHO Revolving Fund -- SIREVA Project -- United Nations Development Program -- United Nations Children's Fund -- Vaccine Independence Initiative -- World Bank -- World Health Organization -- Expanded Program on Immunization -- Program for Vaccine Development -- Children's Vaccine Initiative -- Public-Sector Resources -- Private-Sector Resources -- Nongovernmental Organizations -- Task Force for Child Survival and Development -- Save the Children Fund -- REFERENCES -- 4 Vaccine Demand and Supply -- GLOBAL DEMAND AND SUPPLY -- Demand -- Regional Demand -- Supply -- Procurement -- Innovation -- DEMAND AND SUPPLY IN THE UNITED STATES -- Demand -- Supply -- Pricing -- Vaccine Innovation -- NOTE -- REFERENCES -- 5 Investing in New and Improved Vaccines -- MARKET CONSIDERATIONS -- Market Size -- Intellectual Property -- Patent Rights and Limitations -- Patents and Vaccines -- Infringement -- LIABILITY -- REFERENCES -- 6 Stages of Vaccine Development -- PRIORITY SETTING -- BASIC AND APPLIED RESEARCH -- CLINICAL EVALUATION -- LICENSURE -- PRODUCTION -- Pilot Production -- ScaleUp and Full-Scale Manufacture -- Vaccine Production in Developing Countries -- RECOMMENDATIONS FOR USE -- PROCUREMENT -- DISTRIBUTION AND DELIVERY -- SURVEILLANCE -- Immunization Status -- Monitoring Effectiveness of Vaccines -- Adverse Reactions -- Setting Priorities for Vaccine Use and New Vaccines -- REFERENCES -- 7 A Strategy to Enhance U.S. Participation in the Children's Vaccine Initiative -- A NATIONAL VACCINE AUTHORITY -- Mission -- Functions. Setting Priorities and Product Characterization -- Basic Research -- Applied Research and Exploratory Development -- Intellectual Property Rights -- Product Development -- Clinical Evaluation -- Regulation -- Manufacture -- Procurement -- Monitoring and Evaluation -- Management and Organization -- Funding -- Location -- Points to Consider for Locating the CVI in an Existing Federal Agency -- Options -- U.S. Agency for International Development -- Centers for Disease Control and Prevention -- U.S. Department of Defense -- U.S. Food and Drug Administration -- National Institutes of Health -- The National Vaccine Program -- Independent Organization -- NOTE -- REFERENCES -- Appendixes -- A Relevant Intellectual Property Rights Law -- PATENTS -- Rights and Limitations -- Infringement -- Potential Barriers and Incentives -- First-to-File Versus First-to-Invent -- Backlog in the Patent and Trademark Office -- Costs -- Disclosure to Government Agencies -- Relevant Legislation and Terminology -- Drug Price Competition and Patent Term Restoration Act of 1984 (P.L. 98-417) -- Omnibus Trade and Competitiveness Act (P.L. 100-418) -- Grace Period -- Orphan Drug Act of 1983 (P.L. 99-91) -- Patent and Trademark Amendments of 1980 (P.L 96-517) -- Experimental Use Exception -- TRADE SECRETS (KNOW-HOW) -- Definition -- Confidentiality -- Rights of the Trade Secret Owner -- Rights Against Individuals in Privity -- Protection by Contract -- Implied Contract/Special Relationships -- Rights Against Third Parties -- Additional Rights of a Trade Secret Owner -- Rights to Use Another's Trade Secrets -- REFERENCES -- B National Vaccine Injury Compensation Program -- DEFINITION AND PURPOSE -- BACKGROUND -- FILING A CLAIM UNDER NVICP -- KEY CHARACTERISTICS -- REFERENCES -- C Regulatory Aspects of Vaccine Development, Manufacture, and Distribution -- THE LICENSURE PROCESS. POSTLICENSING -- Manufacture -- Distribution -- THE DRUG EXPORT AMENDMENTS ACT OF 1986 -- REFERENCES -- D Strategies for Achieving Full U.S. Participation in the Children's Vaccine Initiative -- STRATEGY 1: RETAIN THE CURRENT SYSTEM -- Option 1: Increased Funding for CVI Vaccine Research -- Contribution to the Global CVI -- Option 2: Purchase Existing Vaccines -- Contribution to the Global CVI -- Option 3: Improve Vaccine Delivery -- Contribution to the Global CVI -- STRATEGY 2: FORGING NEW PARTNERSHIPS BETWEEN THE PUBLIC AND PRIVATE SECTORS -- Option 1: Broker CVI R& -- D and Pilot Manufacture -- Contribution to the Global CVI -- Option 2: Develop an Entity with CVI-Related R& -- D and Pilot Manufacturing Capabilities -- Contribution to the Global CVI -- STRATEGY 3: EMBARK ON A PUBLIC-SECTOR MODEL -- Contribution to the Global CVI -- E Public Health Service Act (1944) -- PUBLIC LAWS-CH. 373-JULY 1, 1944 PART F-BIOLOGICAL PRODUCTS Regulation of Biological Products -- Interference With Officers -- Penalties for Offenses -- F National Vaccine Program Legislation -- TITLE XXI-VACCINES SUBTITLE 1-NATIONAL VACCINE PROGRAM -- Establishment -- Program Responsibilities -- Plan -- Report -- National Vaccine Advisory Committee -- Authorizations -- G Immunization Schedules -- H Historical Record of Vaccine Product License Holders in the United States -- I Working Group Participants June 11-13, 1992 -- NOTES -- J Committee and Staff Biographies -- K Acronyms. |
Record Nr. | UNINA-9910970771503321 |
Washington, D.C., : National Academy Press, 1993 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Plotkin's vaccines / / Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit |
Edizione | [Seventh edition.] |
Pubbl/distr/stampa | Philadelphia, PA : , : Elsevier, , [2018] |
Descrizione fisica | 1 online resource (xxi, 1644 pages) : illustrations (chiefly color), color maps, portraits (some color) |
Disciplina | 615.3/72 |
Soggetto topico |
Immunization
Vaccines Vaccination Immunization Programs |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | A short history of vaccination -- Vaccine immunology -- Correlates of protection -- The vaccine industry -- Vaccine manufacturing -- Evolution of adjuvants across the centuries -- Vaccine additives and manufacturing residuals in vaccines licensed in the united states -- Passive immunization -- General immunization practices -- Adenovirus vaccines -- Anthrax vaccines -- Biodefense and special pathogen vaccines -- Cancer vaccines -- Cholera vaccines -- Combination vaccines -- Cytomegalovirus vaccines -- Dengue vaccines -- Diarrhea caused by bacteria -- Diphtheria toxoid -- Ebola vaccines -- Enterovirus 71 -- Epstein-Barr virus vaccines -- Haemophilus influenzae type b vaccines -- Hepatitis A vaccines -- Hepatitis B vaccines -- Hepatitis C vaccines -- Hepatitis E vaccines -- Herpes simplex virus vaccines -- Human immunodeficiency virus vaccines -- Human papillomavirus vaccines -- Inactivated influenza vaccines -- Influenza vaccine--live -- Japanese encephalitis vaccines -- Lyme disease vaccines -- Malaria vaccines -- Maternal immunization -- Measles vaccines -- Meningococcal capsular group A, C, W, and Y conjugate vaccines -- Meningococcal capsular group B vaccines -- Mumps vaccines -- Noninfectious disease vaccines -- Norovirus vaccines -- Parasitic disease vaccines -- Pertussis vaccines -- Plague vaccines -- Pneumococcal conjugate vaccine and pneumococcal common protein vaccines -- Pneumococcal polysaccharide vaccines -- Poliovirus vaccine-inactivated -- Poliovirus vaccine-live -- Rabies vaccines -- Respiratory syncytial virus vaccines -- Rotavirus vaccines -- Rubella vaccines -- Smallpox and vaccinia -- Staphylococcus aureus vaccines -- Streptococcus group a vaccines -- Streptococcus group B vaccines -- Tetanus toxoid -- Tickborne encephalitis vaccines -- Tuberculosis vaccines -- Typhoid fever vaccines -- Varicella vaccines -- Yellow fever vaccines -- Zika virus -- Zoster vaccines -- Technologies for making new vaccines -- Development of gene-based vectors for immunization -- Technologies to improve immunization -- Vaccination of immunocompromised hosts -- Vaccination of human immunodeficiency virus-infected persons -- Vaccines for international travel -- Vaccines for healthcare personnel -- Immunization in the united states -- Immunization in Europe -- Immunization in the Asia-Pacific region -- Immunization in developing countries -- Community protection -- Economic analyses of vaccine policies -- Regulation and testing of vaccines -- Regulation of vaccines in Europe -- Regulation of vaccines in low- and middle-income countries -- Vaccine safety -- Legal issues -- Ethics. |
Record Nr. | UNINA-9910583080903321 |
Philadelphia, PA : , : Elsevier, , [2018] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé |
Pubbl/distr/stampa | Genève : , : Organisation mondiale de la Santé, , 2021 |
Descrizione fisica | 1 ressource en ligne (viii, 74 pages) |
Soggetto topico |
Immunization Programs
Socioeconomic Factors National Health Programs Health Priorities Programmes de vaccination Facteurs socioéconomiques Programmes nationaux de santé Priorités en santé |
ISBN | 9789240022317 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | fre |
Record Nr. | UNISA-996486770803316 |
Genève : , : Organisation mondiale de la Santé, , 2021 | ||
![]() | ||
Lo trovi qui: Univ. di Salerno | ||
|
Suivi des inégalités en matière de vaccination : manuel pratique / / Organisation mondiale de la Santé |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Genève : , : Organisation mondiale de la Santé, , 2021 |
Descrizione fisica | 1 ressource en ligne (viii, 74 pages) |
Soggetto topico |
Immunization Programs
Socioeconomic Factors National Health Programs Health Priorities Programmes de vaccination Facteurs socioéconomiques Programmes nationaux de santé Priorités en santé |
ISBN | 9789240022317 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | fre |
Nota di contenuto | Intro -- Foreword -- Acknowledgements -- Abbreviations and acronyms -- Introduction -- About this resource -- Equity Reference Group for Immunization -- Step 1: Determine scope of monitoring -- Overview -- A. Decide on the target population -- b. Identify relevant immunization indicators -- c. Identify relevant dimensions of inequality -- Step 2: Obtain data -- Overview -- A. Conduct data source mapping -- B. Determine whether sufficient data are currently available -- Step 3: Analyse data -- Overview -- A. Prepare disaggregated data -- B. Calculate summary measures of inequality -- Step 4: Report results -- Overview -- A. Define the purpose of reporting and the target audience -- B. Select the scope of reporting -- C. Define the technical content -- D. Decide upon methods of presenting data -- E. Adhere to best practices of reporting -- Step 5: Knowledge translation -- Overview -- Identify priority areas for action -- Integrate equity considerations into immunization programmes and policies -- Identify opportunities for intersectoral collaboration -- Appendix 1. Additional resources -- Appendix 2. Monitoring, Evaluation and Review Framework -- Appendix 3. Double disaggregation -- Appendix 4. Data sources for immunization coverage -- Appendix 5. Overcoming limited data availability -- Appendix 6. Complex measures of inequality -- Appendix 7. Multiple regression analysis and compounded vulnerability -- Appendix 8. Case study: reporting inequalities in immunization -- Glossary. |
Record Nr. | UNINA-9910591156703321 |
Genève : , : Organisation mondiale de la Santé, , 2021 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|